Published on 11 Mar 2026
min read
Views
In MedTech, the speed and quality of innovation is based on a combination of technology capabilities and interoperability. When teams are unable to communicate, share data, or align decisions across functions, the impact is felt everywhere – from design to governance, all the way through to patient outcomes.
Processes become fragmented, issues surface too late, and time-to-market extends, preventing patients from receiving the care they need – when they need it.
This is more than just a technical challenge. With clear goals to deliver better patient care on a global scale, we cannot afford silos to stall innovation. There is a clear need for connected, collaborative, aligned processes that put innovation and patient care at the heart of every decision and every product.
And that starts with your R&D function.
The Real Cost of Siloed MedTech R&D
A siloed R&D approach can lead to:
- Data silos blocking decision-making: When handling such vast quantities of data, critical information can easily get trapped across disconnected platforms, spreadsheets and legacy systems, restricting visibility. It’s estimated that only 24% of healthcare providers effectively leverage their clinical data, preventing MedTech leaders from delivering more data-driven, patient-centric innovations.
- Teams spending more time documenting than innovating: MedTech engineering teams can spend 30-40% of development time on manual documentation processes and updates, instead of on the valuable research and development that fuels innovation. When updates are manual and scattered, regulatory change becomes harder to track, and teams are forced into reactive fire drills instead of proactive risk management.
- AI innovation stalling: Connected, reliable data is key to driving real results from AI. When data remains siloed, AI models are forced to operate with incomplete inputs, limiting real-world application and impact, and increasing the risk of bias.
- Patient care quality suffering: Silos impact more than just operational efficiency. Ultimately, they undermine safety and long-term competitiveness, increasing the likelihood of quality deviations, missed warning signals and administrative burden.
Why Interoperability Is a Strategic Differentiator for Philips
For Philips, interoperability goes beyond an abstract goal. It is the foundation to each of your strategic priorities, defining how you deliver better patient care, build more resilient supply chains, and simplify operations. And importantly, it is the key to innovating faster, safer and more competitively in the MedTech market.
In practice, this means:
- Fewer data silos, so you can accelerate R&D and improve product decisions based on real-world clinical context and applications,
- Shorter development cycles: by partnering with AWS, Philips has already demonstrated how AI-enabled data sharing between Philips PerformanceBridge and hospital systems can help deliver diagnostic informatics solutions faster,
- More personalized, equitable care, using integrated data through platforms like Philips HealthSuite, and
- Operational efficiency, reducing duplicate workflows and allowing engineers to focus on innovation, not manual reconciliation.
Enabling End‑to‑End Interoperability at Philips
Today, interoperability is not just about connecting systems. It is about building the organizational, cultural, technical and data foundations that enable collaborative innovation at scale. By bringing together proven processes, regulated development expertise, and best-in-class technologies, Philips can move faster, integrate smarter, and deliver measurable impact with confidence.
